

TABLE 1

FDA-APPROVED MEDICAL PRODUCTS FOR THE
TREATMENT OF CANCER: AUG. 1, 2015–JULY 31, 2016

Approved Indication	Generic Name	Trade Name	Formulation
Angiogenesis Inhibitors			
Certain form of kidney cancer†	cabozantinib	Cabometyx	☞
Certain form of kidney cancer†	lenvatinib	Lenvima	☞
Cell-signaling Inhibitors			
Certain form of lung cancer†	afatinib	Gilotrif	☞
Certain form of lung cancer	alectinib	Alecensa	☞
Certain form of melanoma	cobimetinib AND vemurafenib*	Cotellic AND Zelboraf	☞
Certain form of lung cancer†	crizotinib	Xalkori	☞
Certain neuroendocrine tumors†	everolimus	Afinitor	☞
Certain form of lung cancer	nectinumab	Portrazza	☞
Certain form of lung cancer	osimertinib*	Tagrisso	☞
Cell-cytoskeleton Modifying Agents			
Liposarcoma†	eribulin mesylate	Halaven	☞
Cell-death Promoting Agents			
Certain form of leukemia	venetoclax	Venclexta	☞
DNA-damaging Agents			
Colorectal cancer	trifluridine AND tipiracil	Lonsurf	☞
Pancreatic cancer	irinotecan liposome injection	Onivyde	☞
Gene-transcription Modifiers			
Liposarcoma and leiomyosarcoma	trabectedin	Yondelis	☞
Immunotherapeutics			
Multiple myeloma	daratumumab	Darzalex	☞
Multiple myeloma	elotuzumab	Empliciti	☞
Melanoma	ipilimumab AND† nivolumab	Yervoy AND Opdivo	☞
Certain types of lung† and kidney† cancers and certain type of lymphoma†	nivolumab	Opdivo	☞
Certain type of lymphoma†	obinutuzumab	Gazyva	☞
Certain type of lung cancer†	pembrolizumab*	Keytruda	☞
Melanoma	talinogene laherparepvec*	Imlygic	☞
Certain type of bladder cancer	atezolizumab	Tecentriq	☞
Proteasome Inhibitors			
Multiple myeloma	ixazomib	Ninlaro	☞
Cancer Screening Tests			
Colorectal cancer	system, colorectal neoplasia, DNA methylation and hemoglobin detection test	Epi proColon	☞
Imaging Agents			
Certain neuroendocrine tumors	gallium (Ga) 68 DOTATATE	Netspot	☞
Prostate cancer	fluciclovine fluorine (F) 18	Axumin	☞
Companion Diagnostic Tests			
Certain type of lung cancer		cobas EGFR Mutation Test v2	☞


*first in class, †new use for 2015–2016, *requires a companion diagnostic

Where multiple trade names are used, only the most common have been listed

American Association for Cancer Research (AACR) Cancer Progress Report 2016

TABLE 2

COMPARISON OF RELATIVE 5-YEAR SURVIVAL RATES
FOR CHILDHOOD CANCERS (0-19 YRS) BETWEEN
1975-79 AND 2006-2012



*Followed into 2012

*Cancers in children and younger adolescents are classified by histology (tissue type) using the International Classification of Childhood Cancers (ICCC)

American Association for Cancer Research (AACR) Cancer Progress Report 2016

TABLE 3 ESTIMATED INCIDENCE AND MORTALITY FOR SELECT CANCERS*

	ESTIMATED 2016 INCIDENCE			ESTIMATED 2016 DEATHS		
	Total	Male	Female	Total	Male	Female
All Sites	1,685,210	841,390	843,820	595,690	314,290	281,400
Head and Neck Region						
Brain & other nervous system	23,770	13,350	10,420	16,050	9,440	6,610
Eye & orbit	2,810	1,510	1,300	280	150	130
Oral cavity & pharynx	48,330	34,780	13,550	9,570	6,910	2,660
Tongue	16,100	11,700	4,400	2,290	1,570	720
Mouth	12,910	7,600	5,310	2,520	1,630	890
Pharynx	16,420	13,350	3,070	3,080	2,400	680
Larynx	13,430	10,550	2,880	3,620	2,890	730
Lung & bronchus	224,390	117,920	106,470	158,080	85,920	72,160
Breast	249,260	2,600	246,660	40,890	440	40,450
Gastrointestinal (GI) System						
Esophagus	16,910	13,460	3,450	15,690	12,720	2,970
Stomach	26,370	16,480	9,890	10,730	6,540	4,190
Liver & intrahepatic bile duct	39,230	28,410	10,820	27,170	18,280	8,890
Gallbladder & other biliary	11,420	5,270	6,150	3,710	1,630	2,080
Pancreas	53,070	27,670	25,400	41,780	21,450	20,330
Small intestine	10,090	5,390	4,700	1,330	710	620
Colon and rectum†	95,270	47,710	47,560	49,190	26,020	23,170
Anus, anal canal, & anorectum	8,080	2,920	5,160	1,080	440	640
Urogenital System						
Kidney & renal pelvis	62,700	39,650	23,050	14,240	9,240	5,000
Ovary	22,280		22,280	14,240		14,240
Uterine corpus	60,050		60,050	10,470		10,470
Uterine cervix	12,990		12,990	4,120		4,120
Urinary bladder	76,960	58,950	18,010	16,390	11,820	4,570
Prostate	180,890	180,890		26,120	26,120	
Testis	8,720	8,720		380	380	
Skin						
Skin (excluding basal & squamous)	83,510	51,650	31,860	13,650	9,330	4,320
Melanoma-skin	76,380	46,870	29,510	10,130	6,750	3,380
Hematological System						
Leukemia	60,140	34,090	26,050	24,400	14,130	10,270
Acute lymphocytic leukemia	6,590	3,590	3,000	1,430	800	630
Chronic lymphocytic leukemia	18,960	10,830	8,130	4,660	2,880	1,780
Acute myeloid leukemia	19,950	11,130	8,820	10,430	5,950	4,480
Chronic myeloid leukemia	8,220	4,610	3,610	1,070	570	500
Lymphoma	81,080	44,960	36,120	21,270	12,160	9,110
Hodgkin lymphoma	8,500	4,790	3,710	1,120	640	480
Non-Hodgkin lymphoma	72,580	40,170	32,410	20,150	11,520	8,630
Myeloma	30,330	17,900	12,430	12,650	6,430	6,220
Other Cancers						
Bones & joints	3,300	1,850	1,450	1,490	860	630
Soft tissue (including heart)	12,310	6,980	5,330	4,990	2,680	2,310

*Rounded to the nearest 10; estimated new cases exclude basal cell and squamous cell skin cancers and in situ carcinomas except urinary bladder. About 61,000 cases of carcinoma in situ of the female breast and 66,480 melanoma in situ will be newly diagnosed in 2016. †Estimated deaths for colon and rectal cancers are combined. ‡More deaths than cases may reflect lack of specificity in recording underlying cause of death on death certificates and/or an undercount in the case estimate.

Source: Estimated new cases are based on cancer incidence rates from 49 states and the District of Columbia during 1995-2012 as reported by the North American Association of Central Cancer Registries (NAACCR), representing about 98% of the U.S. population. Estimated deaths are based on U.S. mortality data during 1997-2012, National Center for Health Statistics, Centers for Disease Control and Prevention.

American Association for Cancer Research (AACR) Cancer Progress Report 2016

TABLE 4

CANCER-CAUSING PATHOGENS

Bacteria

Infectious Agent	Cancer	% of global cancer cases attributable to infection*
<i>Helicobacter pylori</i>	Stomach cancers	32.5

Parasites

Infectious Agent	Cancer	% of global cancer cases attributable to infection*
<i>Clonorchis sinensis</i>	Biliary, gallbladder, and pancreatic cancers	0.1
<i>Opisthorchis viverrini</i>	Biliary, gallbladder, and pancreatic cancers	unknown
<i>Schistosoma haematobium</i>	Bladder cancer	0.3

Viruses

Infectious Agent	Cancer	% of global cancer cases attributable to infection*
Epstein-Barr Virus (EBV)	Hodgkin and certain non-Hodgkin lymphomas, and stomach and nasopharyngeal cancers	5.4
Hepatitis B/C Virus (HBV and HCV)	Hepatocellular carcinoma	29.5
Human Herpes Virus type -8 (HHV-8; also known as Kaposi sarcoma herpes virus)	Kaposi sarcoma and certain forms of lymphoma	2.1
Human Immunodeficiency Virus (HIV)	Kaposi sarcoma and non-Hodgkin lymphoma	unknown
Human Papillomavirus (HPV)	Anal, cervical, head and neck, oral, penile, vaginal, and vulvar cancers	30
Human T-cell Lymphotropic Virus, type 1 (HTLV-1)	T-cell leukemia and lymphoma	0.1
Merkel Cell Polyomavirus (MCV)	Skin cancer	unknown

* where known

American Association for Cancer Research (AACR) Cancer Progress Report 2016

TABLE 5

INHERITED CANCER RISK

Cancers	Syndrome	Associated Gene(s)
Leukemias and lymphomas	Ataxia telangiectasia	ATM
Basal cell carcinoma	Basal cell nevus syndrome	PTCH1, PTCH2, SUFU
All cancers	Bloom syndrome	BLM
Breast, ovarian, pancreatic, and prostate cancers	Breast-ovarian cancer syndrome	BRCA1, BRCA2
Breast, thyroid, and endometrial cancers	Cowden syndrome	PTEN
Breast and stomach cancers	Diffuse gastric and lobular breast cancer syndrome	CDH1
Colorectal cancer	Familial adenomatous polyposis (FAP)	APC
Melanoma and pancreatic cancer	Familial atypical multiple mole-melanoma syndrome (FAMM)	CDKN2A
Retinal cancer	Familial retinoblastoma	RB1
Leukemia	Fanconi's anemia	FACC, FACA
Kidney cancer and uterine fibroids	Hereditary leiomyomatosis and renal cell cancer	FH
Pancreatic cancer	Hereditary pancreatitis/familial pancreatitis	PRSS1, SPINK1
Leukemias, breast, brain, and soft tissue cancers	Li-Fraumeni syndrome	TP53
Colorectal and endometrial cancers	Lynch syndrome	EPCAM, MLH1, MSH2, MSH6, PMS2
Pancreatic cancers, pituitary adenomas, benign skin, and fat tumors	Multiple endocrine neoplasia 1	MEN1
Thyroid cancer and pheochromocytoma	Multiple endocrine neoplasia 2	RET, NTRK1
Pancreatic, liver, lung, breast, ovarian, uterine, and testicular cancers	Peutz-Jeghers syndrome	STK11/LKB1
Tumors of the spinal cord, cerebellum, retina, adrenals, and kidneys	von Hippel-Lindau syndrome	VHL
Kidney cancer	Wilms' tumor	WT1
Skin cancer	Xeroderma pigmentosum	XPB, XPD, XPA

This list is not meant to be exhaustive, but contains some of the more commonly occurring cancer syndromes.

Source: <http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq>

American Association for Cancer Research (AACR) Cancer Progress Report 2016

TABLE 6**SURGERIES FOR THE PREVENTION OF CANCER**

Genetic Mutation(s)	Cancer	Technique	Removes
APC	Colon Cancer	Colectomy	Colon/large intestine
BRCA1 or BRCA2	Breast Cancer	Mastectomy	Breasts
BRCA1 or BRCA2	Ovarian Cancer	Salpingo-oophorectomy	Ovaries and fallopian tubes
CDH1	Stomach Cancer	Gastrectomy	Stomach
RET	Medullary thyroid cancer	Thyroidectomy	Thyroid

American Association for Cancer Research (AACR) Cancer Progress Report 2016

SUPPLEMENTAL TABLE 1
**FDA-APPROVED THERAPEUTICS FOR
CANCER RISK REDUCTION OR TREATMENT
OF PRECANCEROUS CONDITIONS***
Cancer Risk Reduction

Condition	Generic Name	Trade Name
Breast cancer	raloxifene	Evista
	tamoxifen	Nolvadex
Cervical, vulvar, vaginal, and anal cancers and dysplasia; genital warts	human papillomavirus quadrivalent vaccine (types 6, 11, 16, and 18)	Gardasil
Cervical, vulvar, vaginal, and anal cancers and dysplasia; genital warts	human papillomavirus 9-valent vaccine (types 6, 11, 16, 18, 31, 33, 45, 52, and 58)	Gardasil 9
Cervical cancer and cervical dysplasia	human papillomavirus bivalent vaccine (types 16 and 18)	Cervarix

Treatment of Precancerous Conditions

Condition	Generic Name	Trade Name
Actinic keratosis	ingenol mebutate	Picato
	fluorouracil	Adricil
	diclofenac sodium	Voltaren
	5-aminolevulinic acid + photodynamic therapy (pdt)	Actinex
	masoprocol/nordihydroguaiaretic acid	
Bladder dysplasia	bacillus calmette-guerin/BCG	Valstar
	valrubicin	
Esophageal dysplasia	porfimer sodium + photodynamic therapy (PDT)	Photofrin

*adapted from Wu X, Patterson S, Hawk E. Chemoprevention – History and general principles. Best Practice Research Clinical Gastroenterology. 2011;25:445-59.

American Association for Cancer Research (AACR) Cancer Progress Report 2016

SUPPLEMENTAL TABLE 2

FDA-APPROVED THERAPEUTICS FOR THE TREATMENT OF CANCER

DNA-synthesis Inhibitors (Antimetabolites)

Approved Indication	Generic Name	Trade Name
Multiple cancers	5-fluorouracil (5-FU)	Adrucil
Certain leukemias	6-mercaptopurine	Purinethol
Breast and colorectal cancers	capecitabine	Xeloda
Certain leukemias; lymphoma	cladribine	Litrak; Movectro
Certain leukemias	clofarabine	Clolar
Certain leukemias; lymphoma	cytarabine	DepoCyt; Cytosar-U
Stomach cancer	flouxuridine	FUDR
Certain leukemias; lymphoma	fludarabine	Fludara
Breast; lung; ovarian; and pancreatic cancers	gemcitabine	Gemzar
Certain leukemias	hydroxyurea	Droxia
Multiple cancers	methotrexate	Rheumatrex; Trexall
Multiple cancers	mitomycin	Mutamycin
Certain leukemias; lymphoma	nelarabine	Arranon
Lung and ovarian cancers; mesothelioma	pegmetrexed	Alimta
Certain leukemias	pegustatin	Nipent
Certain lymphomas	pralatrexate	Foloty

DNA-damaging Agents

Approved Indication	Generic Name	Trade Name
Ovarian cancer	altretamine	Hexalen
Certain leukemias	arsenic trioxide	Trisenox
Multiple cancers	bendamustine	Treanda
Certain lymphomas; squamous cell and testicular cancers	bleomycin sulfate	Blenoxane
Certain leukemias	busulfan	Myleran; Busulfex
Breast, lung, and ovarian cancers	carboplatin	Paraplatin; Paraplat
Brain tumors; certain lymphomas	carmustine	BICNU
Multiple cancers	chlorambucil	Leukeran
Multiple cancers	cisplatin	Platinol-AQ
Multiple cancers	cyclophosphamide	Cytosan
Melanoma; certain brain cancers	dacarbazine	DTIC-Dome
Multiple cancers	dactinomycin	Cosmegen
Certain leukemias	daunorubicin; daunomycin	Cerubidine
Multiple cancers	doxorubicin hydrochloride	Adriamycin PFS; Adriamycin RDF
Certain leukemias; breast and stomach cancers	epirubicin hydrochloride	Ellence
Testicular and lung cancers	etoposide phosphate	Etopophos; VePesid
Certain leukemias	idamycin	Idamycin PFS
Multiple cancers	ifosfamide	Ifex
Colon, lung, and rectal cancers	irinotecan	Camptosar; Camptosar

INCREASING PRECISION

Cell Cytoskeleton-modifying Agents

Approved Indication	Generic Name	Trade Name
Prostate cancer	cabazitaxel	Jevtana
Prostate cancer	docetaxel	Taxotere
Breast cancer; liposarcoma	eribulin mesylate	Halaven
Breast cancer	ixabepilone	Ixempra
Multiple cancers	paclitaxel	Taxol
Breast, lung, and pancreatic cancers	paclitaxel albumin-bound particles	Abraxane
Multiple cancers	vinorelbine	Velban
Certain leukemias and lymphomas	vincristine	Oncovin
Certain leukemias and lymphomas	vincristine sulfate liposomes	Marqibo
Breast and lung cancers	vinorelbine tartrate	Navelbine

Antinutrients

Approved Indication	Generic Name	Trade Name
Certain leukemias	asparaginase	Elspar; Kidrolase

Gene-transcription Modifiers

Approved Indication	Generic Name	Trade Name
Certain lymphomas	bexarotene	Targetin
Liposarcoma and leiomyosarcoma	trabectedin	Yondelis
Certain leukemias	trifluoromethyl (all-trans retinoic acid)	Vesanoic

Radiation-emitting Drugs

Approved Indication	Generic Name	Trade Name
Prostate cancer	radium Ra 223 dichloride	Xofigo

Cell-death Promoting Agents

Approved Indication	Generic Name	Trade Name
Certain form of leukemia	venetoclax	Venclexta

Hormones/Antihormones

Approved Indication	Generic Name	Trade Name
Prostate cancer	abiraterone	Plenaxis
Prostate cancer	abiraterone acetate	Zytiga
Breast cancer	anastrozole	Arimidex
Prostate cancer	bicalutamide	Casodex
Prostate cancer	degarelix	Firmagon
Prostate cancer	enzalutamide	Xtandi
Prostate cancer	estradiol	Emcyf; Estracyt
Breast cancer	exemestane	Aromasin
Prostate cancer	flutamide	Eulexin
Metastatic breast cancer	fulvestrant	Faslodex
Prostate and breast cancers	goserelin acetate	Zoladex
Breast cancer	letrozole	Femara
Prostate cancer	leuprolide acetate	Eligard; Lupron; Viadur
Breast and endometrial cancers	megestrol acetate	Megace; Megace Oral Suspension
Breast cancer	tamoxifen	Nolvadex
Prostate cancer	triptorelin pamoate	Trestar Depot

Immune-system Modifiers

Approved Indication	Generic Name	Trade Name
Multiple cancers	interferon alfa-2b	Intron A
Melanoma; kidney cancer	aldesleukin	Proleukin
Myelodysplastic syndrome; certain lymphomas	lenalidomide	Revlimid
Multiple myeloma	pomalidomide	Pomalyst

Proteasome Inhibitors

Approved Indication	Generic Name	Trade Name
Multiple myeloma	bortezomib	Velcade
Multiple myeloma	carfilzomib	Kyprolis
Multiple myeloma	ixazomib	Ninlaro

Protein-translation Inhibitors

Approved Indication	Generic Name	Trade Name
Certain type of leukemia	omecaxine mepesuccinate	Synribo

Epigenome-modifying Agents

Approved Indication	Generic Name	Trade Name
Myelodysplastic syndrome	azacitidine	Vidaza
Certain lymphomas	belinostat	Beleodaq
Myelodysplastic syndrome	decabazine	Dacogen
Multiple myeloma	panobinostat	Farydak
Certain lymphomas	romidepsin	Istodax
Certain lymphomas	vorinostat	Zolinza

INCREASING PRECISION

DNA-repair Inhibitors

Approved Indication	Generic Name	Trade Name
Certain form of ovarian cancer*	olaparib	Lynparza

Immune-checkpoint Inhibitors

Approved Indication	Generic Name	Trade Name
Certain type of bladder cancer	atezolizumab	Tecentriq
Melanoma	ipilimumab	Yervoy
Multiple cancers	nivolumab	Opdivo
Melanoma; lung cancer*	pembrolizumab	Keytruda

Bone-remodeling Inhibitors

Approved Indication	Generic Name	Trade Name
Potentially lethal complication of advanced cancers	denosumab	Xgeva

Angiogenesis Inhibitors

Approved Indication	Generic Name	Trade Name
Kidney cancer	axitinib	Inlyta
Multiple cancers	bevacizumab	Avastin
Thyroid cancer; kidney cancer	cabozantinib	Cometriq; Cabometyx
Certain type of thyroid cancer; kidney cancer	lenvatinib	Lenvima

Kidney cancer; soft tissue sarcomas; gastrointestinal stromal tumors	pazopanib	Votrient
--	-----------	----------

Certain types of lung and stomach cancers	ramucicarb	Cyramza
---	------------	---------

Colorectal cancer; gastrointestinal stromal tumors	regorafenib	Stivarga
--	-------------	----------

Kidney cancer; certain type of thyroid cancer	sorafenib	Nexavar
---	-----------	---------

Gastrointestinal stromal tumors; kidney cancer; some pancreatic cancers	sunitinib	Sutent
---	-----------	--------

Thyroid cancer	vandetanib	Caprelsa
----------------	------------	----------

Colorectal cancer	ziv-aflibercept	Zaltrap
-------------------	-----------------	---------

Cell-lysis Mediators

Approved Indication	Generic Name	Trade Name
Certain leukemias	alemtuzumab	Campath
Certain types of leukemia	blinatumomab	Blincyto
Certain lymphomas	brentuximab vedotin	Adcetris
Multiple myeloma	daratumumab	Darzalex
Neuroblastoma	elotuzumab	Unlabeled
Multiple myeloma	ibritumomab	Empliciti
Certain lymphomas	loxorubicin	Zevalin
Certain form of leukemia; certain form of lymphoma	obinutuzumab	Gazyva
Certain leukemias	ofatumumab	Azerra
Certain lymphomas	rituximab	Rituxan

Oncolytic Virus

Approved Indication	Generic Name	Trade Name
Melanoma	talimogene laherparepvec	Imlygic

Therapeutic Vaccines

Approved Indication	Generic Name	Trade Name
Prostate cancer	sipuleucel-T	Provenge

Cell-signaling Inhibitors

Approved Indication	Generic Name	Trade Name
HER2+ breast cancer	ado-trastuzumab emtansine	Kadcyla

Certain type of lung cancer	afatinib	Gilotrif
-----------------------------	----------	----------

Certain form of lung cancer	alecinib	Alecensa
-----------------------------	----------	----------

Certain type of leukemia	bosutinib	Bosulif
--------------------------	-----------	---------

Certain type of metastatic ALK-positive lung cancer	ceritinib	Zykadia
---	-----------	---------

Colon cancer; head and neck cancer	cetuximab	Erbix
------------------------------------	-----------	-------

Certain form of melanoma*	cobimetinib	Cotellic AND Zelboraf
---------------------------	-------------	-----------------------

Specific lung cancers*	crizotinib	Xalkori
------------------------	------------	---------

Some leukemias	dasatinib	Sprycel
----------------	-----------	---------

Certain type of melanoma*	dabrafenib	Tafinlar
---------------------------	------------	----------

Some lung cancers*; pancreatic cancer	erlotinib	Tarceva
---------------------------------------	-----------	---------

Multiple cancers	everolimus	Afinitor
------------------	------------	----------

Lung cancer	gefitinib	Iressa
-------------	-----------	--------

Certain form of lymphoma and non-Hodgkin lymphoma	ibrutinib	Imbruvica
---	-----------	-----------

Certain types of leukemia and lymphoma	idelalisib	Zydelig
--	------------	---------

Some leukemias; stomach cancer; certain type of skin cancer	imatinib	Gleevec; Glivec
---	----------	-----------------

HER2+ breast cancers	lapatinib	Tykerb
----------------------	-----------	--------

Certain form of lung cancer	nectinumab	Portrazza
-----------------------------	------------	-----------

Some leukemias	nilotinib	Tasigna
----------------	-----------	---------

Certain form of lung cancer*	osimertinib	Tagrisso
------------------------------	-------------	----------

Certain subtype of breast cancer	palbociclib	Ibrance
----------------------------------	-------------	---------

Colon cancer	panitumumab	Vectibix
--------------	-------------	----------

HER2+ breast cancer	pertuzumab	Perjeta
---------------------	------------	---------

Certain types of leukemia	ponatinib	Ikclusio
---------------------------	-----------	----------

Myelofibrosis	roxatitinib	Jakafi
---------------	-------------	--------

Most common type of skin cancer	sonidegib	Odorzo
---------------------------------	-----------	--------

Certain types of melanoma*	trametinib	Mekinist
----------------------------	------------	----------

HER2+ breast cancer	trastuzumab	Herceptin
---------------------	-------------	-----------

Kidney cancer	temsirolimus	Torisel; Torisel
---------------	--------------	------------------

Thyroid cancer	vandetanib	Caprelsa
----------------	------------	----------

Melanoma*	vemurafenib	Zelboraf
-----------	-------------	----------

Most common type of skin cancer	vismodegib	Erivedge
---------------------------------	------------	----------

* requires companion diagnostic		
---------------------------------	--	--

Some drugs are available in multiple formulations; these have only been listed once.		
--	--	--

Where multiple trade names are used, only the most common have been listed.		
---	--	--

SURGICAL AND RADIOTHERAPY TREATMENTS FOR CANCER

Surgical Treatments

Used to Treat	Procedure
Breast cancer	Mastectomy
Breast cancer	Lumpectomy
Testicular cancer	Orchiectomy
Multiple head, neck, and chest cancers	Video-Assisted Thoracoscopic Surgery (VATS)
Variety of abdominal cancers	Laparoscopic surgery
Sarcoma and other cancers	Reconstructive and limb-sparing surgeries
Kidney cancer	Partial nephrectomy
Pancreatic cancer	The Whipple/modified Whipple procedure
Stomach-sparing pancreatic surgery for pancreatic cancer	Pancreatoduodenectomy
Rectal cancer	Total mesorectal excision
Prostate cancer	Nerve-sparing prostatectomy
Rectal cancer	Transanal Endoscopic Microsurgery (TEM)
Testicular cancer	Modified retroperitoneal lymph node dissection
Breast, melanoma, and colorectal cancers	Sentinel lymph node biopsies
Multiple cancers	Robotic or computer-assisted surgeries

Radiotherapy Treatments

Used to Treat	Procedure
Prostate, cervical, and other cancers	Brachytherapy
Multiple cancers	Image-Guided Radiation Therapy (IGRT)
Multiple cancers	Intensity Modulated Radiation Therapy (IMRT)
Brain metastases	Stereotactic radiosurgery
Liver and lung cancers	Stereotactic body radiation therapy
Multiple cancers	Neoadjuvant and adjuvant radiotherapy combined with radiation therapy
Head and neck cancers	Radiation therapy combined with molecularly targeted therapy (cetuximab)
Prostate cancer	Radiation therapy combined with androgen deprivation
Prostate cancer	Adjuvant radiotherapy
Pediatric cancers	Proton therapy
Unresectable, glioblastoma, lung cancer, head and neck cancer, esophagus cancer, pancreatic cancer	Concurrent chemotherapy and radiation therapy
Anal cancer, head and neck cancer	Radiation with chemotherapy can produce cure with organ preservation
Breast cancer	Radiation and surgery (with or without chemotherapy) can produce cure with organ preservation

American Association for Cancer Research (AACR) Cancer Progress Report 2016